36
Participants
Start Date
June 1, 2018
Primary Completion Date
December 20, 2022
Study Completion Date
December 20, 2022
DSP-0509
Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump.
DSP-0509, Pembrolizumab
Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (200 mg IV q3w)
DSP-0509, Pembrolizumab
Each patient treated will receive DSP-0509 at the Recommended Phase II Dose (RP2D) level as determined in Part B. It is given as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (400 mg IV q6w)
Fox Chase Cancer Center, Philadelphia
University of North Carolina at Chapel Hill, Chapel Hill
Henry-Joyce Cancer Center, Vanderbilt University, Nashville
Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis
M.D. Anderson Cancer Center, The University of Texas, Houston
Collaborators (1)
Syneos Health
OTHER
Sumitomo Pharma America, Inc.
INDUSTRY